REQORSA® gene therapy shows promise against hard-to-treat ALK-positive non-small cell lung cancer
Clinical-stage gene therapy developer Genprex (GNPX) announced that new preclinical data from its lead drug candidate, REQORSA® (quaratusugene ozeplasmid), will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics later this month. The conference, a major global oncology event, is scheduled for October 22–26, 2025 at the Hynes Convention Center in Boston, Massachusetts.
The data, generated in collaboration with Genprex’s research partners, focuses on ALK-EML4 positive non-small cell lung cancer (NSCLC)—a rare but aggressive form of lung cancer that primarily affects younger, non-smoking patients. According to the company, REQORSA demonstrated a strong pro-apoptotic effect, meaning it was able to trigger cancer cell death in preclinical models.
“We are thrilled that our collaborators have once again been selected to present positive preclinical data on the use of REQORSA,” said Ryan Confer, President and CEO of Genprex. “These data further validate REQORSA as a potential treatment for many types of cancer, including this challenging subset of lung cancer. We look forward to advancing our studies of REQORSA in combination with ALK inhibitors.”
The featured poster at the conference is titled:
“Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing non-small cell lung carcinoma induces apoptosis and is highly effective in preclinical studies.”
REQORSA works by delivering a tumor suppressor gene known as TUSC2, which is often missing or inactivated in cancers. Unlike traditional gene therapies, Genprex uses a non-viral delivery platform, potentially reducing safety risks associated with viral vectors.
The news adds to growing momentum around Genprex’s development pipeline, which also includes clinical trials evaluating REQORSA in combination with AstraZeneca’s Tagrisso and Merck’s Keytruda for other forms of lung cancer. Investors have viewed today’s announcement as a positive validation signal for Genprex’s platform technology and oncology strategy.
With gene therapy continuing to redefine cancer treatment possibilities, Genprex’s upcoming presentation will be closely watched by researchers, biotech investors, and potential pharmaceutical partners seeking novel tumor-targeting strategies.
You might like this article:Australian Oilseeds Holdings Surges on Strong Export Demand and Rising Global Vegetable Oil Prices
